Huntington's Disease

Genetic MONDO:0007739 Pathograph 5 Neurodegenerative Disorder Movement Disorder

Ask OpenScientist

Ask a research question about Huntington's Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
1
Inheritance
7
Pathophysiology
0
Histopathology
7
Phenotypes
4
Hypotheses
5
Pathograph
13
Genes
7
Treatments
2
Subtypes
0
Differentials
0
Datasets
0
Trials
0
Models
6
References
2
Deep Research
🏷

Classifications

Harrison's Chapter
nervous system disorder neurodegenerative disease movement disorder
👪

Inheritance

1
Autosomal Dominant
Show evidence (3 references)
PMID:29325616 SUPPORT
"Huntington disease is a monogenic neurodegenerative disorder that displays an autosomal-dominant pattern of inheritance."
The literature explicitly states that Huntington's disease follows an autosomal-dominant pattern of inheritance.
PMID:28803251 SUPPORT
"Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of CAG triplet repeat."
The literature confirms that Huntington's disease is an autosomal dominant disorder.
PMID:36352624 SUPPORT
"Huntington's Disease (HD) is an autosomal dominant, progressive neuropsychiatric illness caused by CAG repeat expansion."
The literature supports that Huntington's disease is inherited in an autosomal dominant manner.
◆

Subtypes

2
Juvenile Huntington's Disease
A rare, early-onset form that begins in childhood or adolescence and progresses more rapidly than typical forms.
Show evidence (4 references)
PMID:26557176 SUPPORT
"Huntington's disease (HD) is a rare dominantly inherited neurodegenerative disorder... As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions."
The abstract describes a case of childhood-onset Huntington's disease that progresses rapidly, supporting the statement.
PMID:36318082 SUPPORT
"Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years... The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE."
The abstract confirms that Juvenile Huntington's Disease is rare, begins early, and progresses rapidly, supporting the statement.
PMID:14584235 SUPPORT
"The presentation of juvenile Huntington's disease can cause diagnostic difficulties. The genetics and pathogenesis of the condition are discussed."
The abstract acknowledges the existence of juvenile Huntington's disease, which supports the statement.
+ 1 more reference
Late-Onset Huntington's Disease
Typically begins after the age of 50 and may have a slower progression.
Show evidence (4 references)
PMID:28671137 PARTIAL
"BACKGROUND: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."
The statement that Huntington's Disease typically begins after the age of 50 is not entirely accurate. While late-onset Huntington's Disease (LoHD) does occur, the typical age of onset for HD is in the fourth decade. However, the statement is partially supported by the fact that some individuals do experience late onset, and LoHD may have a slower progression.
PMID:17390259 REFUTE
"Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment."
This reference refutes the statement that Huntington's Disease typically begins after the age of 50. It states that HD most typically manifests between the ages of 35 and 45 years.
PMID:36318082 NO_EVIDENCE
"Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years."
This reference discusses Juvenile-onset Huntington's Disease, which is not relevant to the claim about typical onset after the age of 50.
+ 1 more reference
◈

Mechanistic Hypotheses

4
Toxic Gain-of-Function (Polyglutamine Aggregation)
canonical_toxic_gain_of_function CANONICAL
The expanded polyglutamine tract in mutant huntingtin confers a toxic gain-of-function through protein misfolding, oligomerization, and aggregation into inclusion bodies. This is the widely accepted primary disease mechanism, with polyQ expansion beyond the pathogenic threshold (~36 repeats) driving neurodegeneration predominantly in the striatum.
Pathograph links
CAG Repeat Expansion in the HTT Gene -> Mutant Huntingtin Protein Aggregation DIRECT Expanded HTT generates a polyglutamine-expanded huntingtin species that misfolds and accumulates in oligomers, fibrils, and inclusions.
CAG Repeat Expansion in the HTT Gene -> Transcriptional Dysregulation INDIRECT KNOWN INTERMEDIATES The expanded HTT allele alters neuronal gene expression through mutant huntingtin interactions with transcriptional regulators. Intermediates: nuclear mutant huntingtin; disrupted Sp1/CBP/REST-NRSF interactions
Show evidence (2 references)
PMID:22180703 SUPPORT Other
"It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum."
Explicitly names the toxic gain-of-function phenotype as the consequence of polyQ expansion and links it to striatal neurodegeneration.
PMID:25336039 SUPPORT Other
"The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions."
Directly states the toxic gain-of-function framing and details the aggregation cascade from proteolysis through misfolding to inclusion body formation.
Transcriptional Dysregulation
canonical_transcriptional_dysregulation CANONICAL
Mutant huntingtin disrupts transcriptional regulation by sequestering key transcription factors and co-activators (Sp1, CBP, REST/NRSF), leading to widespread downregulation of neuronal survival genes including BDNF. This is a canonical downstream mechanistic layer in HD, linking mutant huntingtin protein interactions to loss of neuronal maintenance programs.
Pathograph links
CAG Repeat Expansion in the HTT Gene -> Transcriptional Dysregulation INDIRECT KNOWN INTERMEDIATES The expanded HTT allele alters neuronal gene expression through mutant huntingtin interactions with transcriptional regulators. Intermediates: nuclear mutant huntingtin; disrupted Sp1/CBP/REST-NRSF interactions
Transcriptional Dysregulation -> Mitochondrial Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Intermediates: reduced PGC-1alpha activity; impaired mitochondrial biogenesis and antioxidant defense
Show evidence (8 references)
PMID:11839795 SUPPORT Model Organism
"In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin."
In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
PMID:11839795 SUPPORT In Vitro
"Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells."
Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
PMID:11264541 SUPPORT In Vitro
"We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain."
HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
+ 5 more references
Mitochondrial Dysfunction and Bioenergetic Failure
canonical_mitochondrial_bioenergetic_failure CANONICAL
Mutant huntingtin impairs mitochondrial function through reduced oxidative phosphorylation complex activity, disrupted calcium homeostasis, and transcriptional repression of PGC-1alpha. This is a canonical convergent mechanism in HD that links transcriptional dysregulation and mutant huntingtin stress to bioenergetic failure, oxidative damage, and neuronal death, particularly in energy-demanding striatal medium spiny neurons.
Pathograph links
Transcriptional Dysregulation -> Mitochondrial Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Intermediates: reduced PGC-1alpha activity; impaired mitochondrial biogenesis and antioxidant defense
Show evidence (2 references)
PMID:19622387 SUPPORT Other
"Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death."
Frames mitochondrial dysfunction as a key pathogenic mechanism linking compromised energy metabolism and oxidative damage to neuronal death.
PMID:23602910 SUPPORT Other
"There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma..."
Links PGC-1alpha impairment to mitochondrial dysfunction in HD, connecting transcriptional dysregulation of mitochondrial biogenesis genes to bioenergetic failure.
NMDA Receptor-Mediated Excitotoxicity
alternative_excitotoxicity ALTERNATIVE
Historical but still supported superimposed model proposing that mutant huntingtin and corticostriatal circuit dysfunction enhance NMDA receptor-mediated excitotoxicity in striatal medium spiny neurons. This hypothesis is best viewed as a selective-vulnerability amplifier rather than the sole initiating lesion.
Pathograph links
CAG Repeat Expansion in the HTT Gene -> Excitotoxicity INDIRECT KNOWN INTERMEDIATES The expanded HTT allele increases vulnerability to NMDAR-driven glutamatergic injury in striatal medium spiny neurons. Intermediates: altered NMDAR function; corticostriatal glutamatergic stress
Show evidence (2 references)
PMID:17188796 SUPPORT Other
"Many lines of evidence support a role for neuronal damage arising as a result of excessive activation of glutamate receptors by excitatory amino acids in the pathogenesis of Huntington disease. The N-methyl-d-aspartate subclass of ionotropic glutamate receptors (NMDARs) is more selective and..."
Comprehensive review establishing NMDAR-mediated excitotoxicity as a key pathogenic mechanism in HD with evidence from human tissue, animal models, and cell-based systems.
PMID:19279257 SUPPORT Model Organism
"This is the first direct in vivo evidence of NR2B-NMDAR-mediated excitotoxicity in the context of HD. Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD."
Provides the first direct in vivo genetic evidence for the excitotoxicity hypothesis by showing exacerbated striatal neurodegeneration when NR2B-NMDAR subunits are overexpressed in an HD mouse model.
⚙

Pathophysiology

7
CAG Repeat Expansion in the HTT Gene
Mutation characterized by an expanded number of CAG repeats, which encodes an abnormal polyglutamine tract in the huntingtin protein.
NMDA Receptor-Mediated Excitotoxicity Toxic Gain-of-Function (Polyglutamine Aggregation) Transcriptional Dysregulation
DNA mismatch repair link
striatum link cerebral cortex link
Downstream
Mutant Huntingtin Protein Aggregation Expanded HTT generates a polyglutamine-expanded huntingtin species that misfolds and accumulates in oligomers, fibrils, and inclusions. Toxic Gain-of-Function (Polyglutamine Aggregation)
Transcriptional Dysregulation The expanded HTT allele alters neuronal gene expression through mutant huntingtin interactions with transcriptional regulators. Toxic Gain-of-Function (Polyglutamine Aggregation) Transcriptional Dysregulation
Excitotoxicity The expanded HTT allele increases vulnerability to NMDAR-driven glutamatergic injury in striatal medium spiny neurons. NMDA Receptor-Mediated Excitotoxicity
Show evidence (5 references)
PMID:7620118 SUPPORT
"Early in 1993, an unstable, expanded trinucleotide repeat in a novel gene of unknown function was identified on HD chromosomes. This discovery unleased a flurry of experimentation that has established the expanded CAG repeat the almost universal cause of the characteristic neurologic symptoms..."
The reference confirms that an expanded CAG repeat in the HTT gene is the cause of Huntington's Disease.
PMID:35395060 SUPPORT
"Huntington's disease (HD) is caused by an expansion of the CAG trinucleotide repeat domain in the huntingtin gene that results in expression of a mutant huntingtin protein (mHTT) containing an expanded polyglutamine tract in the amino terminus."
The literature clearly states that HD is caused by an expanded CAG repeat in the HTT gene, leading to a mutant huntingtin protein with an abnormal polyglutamine tract.
PMID:27529325 SUPPORT
"Huntington's disease (HD) belongs to the group of inherited polyglutamine (PolyQ) diseases caused by an expanded CAG repeat in the coding region of the Huntingtin (HTT) gene that results in an elongated polyQ stretch."
This reference supports the statement by specifying that HD is caused by an expanded CAG repeat in the HTT gene, leading to an elongated polyglutamine stretch.
+ 2 more references
Mutant Huntingtin Protein Aggregation
Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.
medium spiny neuron link
protein aggregation link autophagy link
striatum link cerebral cortex link
Show evidence (5 references)
PMID:35319359 SUPPORT
"Pathogenesis of HD involves cleavage of the huntingtin protein followed by the neuronal accumulation of its aggregated form."
The literature supports that the pathogenesis of Huntington's Disease involves the accumulation of aggregated mutant huntingtin protein, leading to neuronal dysfunction and death.
PMID:12657365 SUPPORT
"The initial and primary target of degeneration in HD is the striatal medium spiny GABAergic neuron, and by end stages of the disease up to 95% of these neurons are lost."
This reference supports the statement by highlighting the primary degeneration of neurons in the striatum due to Huntington's Disease.
PMID:31813995 SUPPORT
"Mutant HTT (mHTT) toxicity is caused by its aggregation/oligomerization. The striatum is the most vulnerable region, although all brain regions undergo neuronal degeneration in the disease."
This literature supports the statement by confirming that mutant huntingtin protein aggregation leads to neurotoxicity, particularly in the striatum.
+ 2 more references
Excitotoxicity
Overactivation of glutamate receptors leading to neuronal damage.
medium spiny neuron link astrocyte link
chemical synaptic transmission link excitatory postsynaptic potential link response to oxidative stress link
striatum link
Show evidence (4 references)
PMID:38776957 SUPPORT
"We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD."
The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.
PMID:1464368 SUPPORT
"Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases."
This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.
PMID:7590394 SUPPORT
"Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA."
The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.
+ 1 more reference
Mitochondrial Dysfunction
Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.
medium spiny neuron link astrocyte link
oxidative phosphorylation link mitochondrion organization link response to oxidative stress link
striatum link cerebral cortex link
Show evidence (2 references)
PMID:19622387 SUPPORT Other
"Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death."
Supports the pathophysiology entry by directly linking mitochondrial dysfunction in HD to compromised energy metabolism, oxidative damage, and neuronal death.
PMID:23602910 SUPPORT Other
"There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma..."
Supports the mitochondrial dysfunction mechanism by connecting impaired PGC-1alpha activity to defective mitochondrial biogenesis, metabolism, and antioxidant defense in HD.
Neuroinflammation
Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.
microglial cell link astrocyte link
inflammatory response link microglial cell activation link
striatum link
D2 Receptor Medium Spiny Neuron Selective Vulnerability
D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.
medium spiny neuron link
protein aggregation link synaptic transmission link
striatum link
Transcriptional Dysregulation
Mutant huntingtin disrupts transcriptional regulation through sequestration of transcription factors including Sp1, CBP, and REST/NRSF, leading to widespread downregulation of neuronal genes including BDNF.
Mitochondrial Dysfunction and Bioenergetic Failure Transcriptional Dysregulation
medium spiny neuron link
regulation of transcription by RNA polymerase II link chromatin remodeling link
striatum link cerebral cortex link
Downstream
Mitochondrial Dysfunction Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Transcriptional Dysregulation Mitochondrial Dysfunction and Bioenergetic Failure
Show evidence (8 references)
PMID:11839795 SUPPORT Model Organism
"In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin."
In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
PMID:11839795 SUPPORT In Vitro
"Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells."
Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
PMID:11264541 SUPPORT In Vitro
"We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain."
HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
+ 5 more references
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Huntington's Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Digestive 1
Dysphagia Dysphagia (HP:0002015)
Nervous System 5
Chorea Chorea (HP:0002072)
Show evidence (5 references)
PMID:24176425 SUPPORT
"Huntington disease (HD) is an autosomal dominant, adult-onset, progressive neurodegenerative disease characterized by the triad of abnormal movements (typically chorea), cognitive impairment, and psychiatric problems."
The reference clearly states that chorea is a characteristic abnormal movement in Huntington's Disease.
PMID:36049455 SUPPORT
"Chorea is one of the major manifestations of Huntington's disease."
This reference confirms that chorea is a major manifestation of Huntington's Disease.
PMID:31707371 SUPPORT
"BACKGROUND: Anosognosia, or unawareness of illness of deficits, has been observed in Huntington's disease (HD) in relation to motor and cognitive signs and symptoms. Most studies of awareness in HD have used self-report questionnaire methodology rather than asking patients to report on their..."
The reference mentions chorea in the context of Huntington's Disease, supporting the statement.
+ 2 more references
Dystonia Dystonia (HP:0001332)
Bradykinesia Bradykinesia (HP:0002067)
Cognitive Impairment Cognitive impairment (HP:0100543)
Depression Depression (HP:0000716)
Growth 1
Weight Loss Weight loss (HP:0001824)
🧬

Genetic Associations

13
HTT (Pathogenic CAG Repeat Expansion)
Autosomal Dominant
Show evidence (11 references)
PMID:27188817 SUPPORT
"Huntington disease is devastating to patients and their families - with autosomal dominant inheritance... The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin."
The literature explicitly states that Huntington's disease is caused by an expanded CAG trinucleotide repeat in the HTT gene and is inherited in an autosomal dominant manner.
PMID:33579864 SUPPORT
"Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of the HTT CAG repeat."
This reference confirms that Huntington's disease is caused by the expansion of the HTT CAG repeat and follows an autosomal dominant inheritance pattern.
PMID:31820322 SUPPORT
"Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene."
This source supports the statement by indicating that Huntington's disease is an autosomal dominant disorder caused by a CAG expansion in the HTT gene.
+ 8 more references
MSH3 (Genetic Modifier)
MLH1 (Genetic Modifier)
PMS1 (Genetic Modifier)
PMS2 (Genetic Modifier)
LIG1 (Genetic Modifier)
PPARGC1A (Pathophysiological Role)
SLC1A2 (Pathophysiological Role)
BDNF (Pathophysiological Role)
NTRK2 (Pathophysiological Role)
DRD1 (Pathophysiological Role)
DRD2 (Pathophysiological Role)
SQSTM1 (Pathophysiological Role)
💊

Treatments

7
Tetrabenazine
Action: pharmacotherapy MAXO:0000058
Agent: tetrabenazine ↗
Used to manage chorea by depleting dopamine.
Show evidence (4 references)
PMID:24366610 SUPPORT
"Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects."
This reference confirms that tetrabenazine is used to manage chorea in Huntington's Disease by depleting dopamine.
PMID:20869622 SUPPORT
"Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease."
This reference confirms that tetrabenazine depletes monoamines, including dopamine, to manage chorea in Huntington's Disease.
PMID:20442355 SUPPORT
"Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting in monoamine depletion."
This reference supports that tetrabenazine depletes dopamine to manage chorea in Huntington's Disease.
+ 1 more reference
Antipsychotic Medications
Action: pharmacotherapy MAXO:0000058
Used for psychiatric symptoms like irritability and agitation.
Show evidence (3 references)
PMID:27534434 SUPPORT
"In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms..."
The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.
PMID:16383221 SUPPORT
"According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy."
The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.
PMID:36496108 SUPPORT
"Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease..."
Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.
Selective Serotonin Reuptake Inhibitors (SSRIs)
Action: pharmacotherapy MAXO:0000058
Used to manage depression.
Show evidence (2 references)
PMID:18394562 SUPPORT
"Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants..."
The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.
PMID:22119091 SUPPORT
"Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)..."
The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.
Physical Therapy
Action: physical therapy MAXO:0000011
Helps maintain mobility and function.
Show evidence (3 references)
PMID:31907286 SUPPORT
"There is strong evidence to support physical therapy interventions to improve fitness, motor function, and gait in persons with HD."
The review provides strong evidence that physical therapy interventions improve fitness, motor function, and gait in people with Huntington's Disease, supporting the statement that physical therapy helps maintain mobility and function.
PMID:31177235 SUPPORT
"Prior Huntington''s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life."
The study indicates that ancillary services, which include physical therapy, improve motor symptoms in HD patients, supporting the statement that physical therapy helps maintain mobility and function.
PMID:25062860 SUPPORT
"TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures."
The study identifies specific mobility measures that are effective for assessing and optimizing mobility in HD patients, supporting the statement that physical therapy helps maintain mobility and function.
Speech Therapy
Action: behavioral counseling MAXO:0000077
Helps manage dysarthria and dysphagia.
Show evidence (3 references)
PMID:28983422 PARTIAL
"SLPs play an important role in the evaluation and management of dysarthria and dysphagia."
The literature indicates that speech-language pathologists (SLPs) play a significant role in managing dysarthria and dysphagia in patients with hyperkinetic disorders, including Huntington's Disease. However, it does not explicitly state that speech therapy helps manage these conditions in HD specifically.
PMID:33577706 PARTIAL
"Findings shed a light on everyday communication challenges faced by people with HD and their professional caregivers, and the lack of implementation of communication aids in this group."
The literature highlights the importance of including speech and language therapists in the care of HD patients, indicating a supportive role. However, it does not provide explicit evidence that speech therapy directly helps manage dysarthria and dysphagia in HD.
PMID:31989345 NO_EVIDENCE
"The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature."
The literature states that the impact of rehabilitative treatments, including speech therapy, on dysphagia in HD has been minimally studied, providing no clear evidence of its efficacy.
Occupational Therapy
Action: physical therapy MAXO:0000011
Assists with daily living activities.
Show evidence (3 references)
PMID:28947114 PARTIAL
"Lifestyle factors, such as activity level and exercise, as well as specific motor training may be helpful in managing the functional sequelae of HD and possibly slowing disease progression."
The literature suggests that rehabilitation interventions, including motor training, can help manage functional abilities in HD, which implies a supportive role in daily living activities. However, it does not explicitly mention occupational therapy or daily living activities directly.
PMID:36055643 PARTIAL
"This objective burden increased with higher functional loss of the HD individual and with more severe cognitive-behavioral disorders."
This study discusses the burden on informal caregivers and the functional loss in HD individuals, indicating a need for supportive roles, which could include occupational therapy. However, it does not explicitly mention occupational therapy.
PMID:31177235 SUPPORT
"Prior Huntington's disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear."
The literature explicitly mentions that ancillary services, which include occupational therapy, improve various aspects of life for HD patients, indicating a supportive role in daily living activities.
Genetic Counseling
Action: genetic counseling MAXO:0000079
Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.
🌍

Environmental Factors

1
None Applicable
Show evidence (10 references)
PMID:20591965 NO_EVIDENCE
"Huntington's disease."
The provided reference does not mention anything about 'None Applicable' in relation to Huntington's Disease.
PMID:1535663 NO_EVIDENCE
"What ethical justification can be found for informing a person that he or she will later develop a lethal disease for which no therapy is available?"
The provided reference discusses the ethics of genetic prediction and testing for Huntington's Disease but does not mention 'None Applicable' as a value.
PMID:29856024 NO_EVIDENCE
"Huntington's disease (HD) is a monogenic, autosomal dominant inherited fatal disease that affects 1 in 10,000 people worldwide."
The provided reference discusses nonhuman primate models for Huntington's Disease but does not mention 'None Applicable' as a value.
+ 7 more references
🔬

Biochemical Markers

1
Elevated Neuronal Inclusions (Positive)
Show evidence (4 references)
PMID:22200539 SUPPORT
"Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs)."
The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.
PMID:38810948 SUPPORT
"We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients."
The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.
PMID:19172113 SUPPORT
"It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species."
The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.
+ 1 more reference
{ }

Source YAML

click to show 
name: Huntington's Disease
creation_date: '2025-12-04T16:57:31Z'
updated_date: '2026-04-08T17:46:38Z'
category: Genetic
parents:
- Neurodegenerative Disorder
- Movement Disorder
synonyms:
- Huntington's Chorea
has_subtypes:
- name: Juvenile Huntington's Disease
  description: A rare, early-onset form that begins in childhood or adolescence and progresses more rapidly than typical forms.
  evidence:
  - reference: PMID:26557176
    reference_title: "Childhood-onset (Juvenile) Huntington's disease: A rare case report."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a rare dominantly inherited neurodegenerative disorder... As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions.
    explanation: The abstract describes a case of childhood-onset Huntington's disease that progresses rapidly, supporting the statement.
  - reference: PMID:36318082
    reference_title: "Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease."
    supports: SUPPORT
    snippet: Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years... The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE.
    explanation: The abstract confirms that Juvenile Huntington's Disease is rare, begins early, and progresses rapidly, supporting the statement.
  - reference: PMID:14584235
    reference_title: "Huntington's disease of early onset or juvenile Huntington's disease."
    supports: SUPPORT
    snippet: The presentation of juvenile Huntington's disease can cause diagnostic difficulties. The genetics and pathogenesis of the condition are discussed.
    explanation: The abstract acknowledges the existence of juvenile Huntington's disease, which supports the statement.
  - reference: PMID:2942452
    reference_title: "Juvenile Huntington disease."
    supports: SUPPORT
    snippet: Of 195 cases of juvenile Huntington disease gathered from case descriptions... It is argued that juvenile Huntington disease should not be regarded as a separate clinical entity, but as a manifestation of the rigid variant of the disease.
    explanation: The abstract discusses juvenile Huntington's disease and its characteristics, supporting the statement.
- name: Late-Onset Huntington's Disease
  description: Typically begins after the age of 50 and may have a slower progression.
  evidence:
  - reference: PMID:28671137
    reference_title: "What do we know about Late Onset Huntington's Disease?"
    supports: PARTIAL
    snippet: 'BACKGROUND: Although the typical age of onset for Huntington''s disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age).'
    explanation: The statement that Huntington's Disease typically begins after the age of 50 is not entirely accurate. While late-onset Huntington's Disease (LoHD) does occur, the typical age of onset for HD is in the fourth decade. However, the statement is partially supported by the fact that some individuals do experience late onset, and LoHD may have a slower progression.
  - reference: PMID:17390259
    reference_title: "Huntington's Disease."
    supports: REFUTE
    snippet: Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment.
    explanation: This reference refutes the statement that Huntington's Disease typically begins after the age of 50. It states that HD most typically manifests between the ages of 35 and 45 years.
  - reference: PMID:36318082
    reference_title: "Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease."
    supports: NO_EVIDENCE
    snippet: Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years.
    explanation: This reference discusses Juvenile-onset Huntington's Disease, which is not relevant to the claim about typical onset after the age of 50.
  - reference: PMID:28087720
    reference_title: "A liminal stage after predictive testing for Huntington disease."
    supports: NO_EVIDENCE
    snippet: Following predictive testing for Huntington disease (HD), knowledge of one's carrier status may have consequences on disease onset.
    explanation: This reference does not provide information relevant to the typical age of onset or progression of Huntington's Disease.
prevalence:
- population: Global
  percentage: 0.004-0.01
  evidence:
  - reference: PMID:1535611
    reference_title: "The epidemiology of Huntington's disease."
    supports: PARTIAL
    snippet: It is concluded that most European populations, both Northern and Southern, show a relatively high prevalence (4-8 per 100,000), and that the disorder may also be frequent in India and parts of central Asia. HD is notably rare in Finland and in Japan, but data for Eastern Asia and Africa are inadequate.
    explanation: The prevalence of Huntington's Disease varies significantly across different regions, with some populations showing higher prevalence and others showing lower. Therefore, a global percentage of 0.004-0.01 may not accurately reflect the variability seen in different regions.
  - reference: PMID:28671137
    reference_title: "What do we know about Late Onset Huntington's Disease?"
    supports: NO_EVIDENCE
    snippet: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age).
    explanation: This reference discusses the age of onset and not the global prevalence.
inheritance:
- name: Autosomal Dominant
  evidence:
  - reference: PMID:29325616
    reference_title: "Huntington disease."
    supports: SUPPORT
    snippet: Huntington disease is a monogenic neurodegenerative disorder that displays an autosomal-dominant pattern of inheritance.
    explanation: The literature explicitly states that Huntington's disease follows an autosomal-dominant pattern of inheritance.
  - reference: PMID:28803251
    reference_title: "Epidemiological Study of Huntington's Disease in the Province of Ferrara, Italy."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of CAG triplet repeat.
    explanation: The literature confirms that Huntington's disease is an autosomal dominant disorder.
  - reference: PMID:36352624
    reference_title: "Complexities in Genetic Counseling and Testing of Huntington's Disease: A Perspective from India."
    supports: SUPPORT
    snippet: Huntington's Disease (HD) is an autosomal dominant, progressive neuropsychiatric illness caused by CAG repeat expansion.
    explanation: The literature supports that Huntington's disease is inherited in an autosomal dominant manner.
pathophysiology:
- name: CAG Repeat Expansion in the HTT Gene
  description: Mutation characterized by an expanded number of CAG repeats, which encodes an abnormal polyglutamine tract in the huntingtin protein.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: DNA mismatch repair
    term:
      id: GO:0006298
      label: mismatch repair
  evidence:
  - reference: PMID:7620118
    reference_title: "Huntington's disease."
    supports: SUPPORT
    snippet: Early in 1993, an unstable, expanded trinucleotide repeat in a novel gene of unknown function was identified on HD chromosomes. This discovery unleased a flurry of experimentation that has established the expanded CAG repeat the almost universal cause of the characteristic neurologic symptoms and pathology of this neurodegenerative disorder of midlife onset.
    explanation: The reference confirms that an expanded CAG repeat in the HTT gene is the cause of Huntington's Disease.
  - reference: PMID:35395060
    reference_title: "Development of mAb-based polyglutamine-dependent and polyglutamine length-independent huntingtin quantification assays with cross-site validation."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is caused by an expansion of the CAG trinucleotide repeat domain in the huntingtin gene that results in expression of a mutant huntingtin protein (mHTT) containing an expanded polyglutamine tract in the amino terminus.
    explanation: The literature clearly states that HD is caused by an expanded CAG repeat in the HTT gene, leading to a mutant huntingtin protein with an abnormal polyglutamine tract.
  - reference: PMID:27529325
    reference_title: "RNA toxicity induced by expanded CAG repeats in Huntington's disease."
    supports: SUPPORT
    snippet: Huntington's disease (HD) belongs to the group of inherited polyglutamine (PolyQ) diseases caused by an expanded CAG repeat in the coding region of the Huntingtin (HTT) gene that results in an elongated polyQ stretch.
    explanation: This reference supports the statement by specifying that HD is caused by an expanded CAG repeat in the HTT gene, leading to an elongated polyglutamine stretch.
  - reference: PMID:33579866
    reference_title: "What is the Pathogenic CAG Expansion Length in Huntington's Disease?"
    supports: SUPPORT
    snippet: Huntington's disease (HD) (OMIM 143100) is caused by an expanded CAG repeat tract in the HTT gene.
    explanation: The reference supports the statement, confirming that HD is caused by an expanded CAG repeat in the HTT gene.
  - reference: PMID:31398342
    reference_title: "CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset."
    supports: SUPPORT
    snippet: Variable, glutamine-encoding, CAA interruptions indicate that a property of the uninterrupted HTT CAG repeat sequence, distinct from the length of huntingtin's polyglutamine segment, dictates the rate at which Huntington's disease (HD) develops.
    explanation: This reference supports the statement by discussing the role of uninterrupted CAG repeats in the HTT gene in the development of HD.
  downstream:
  - target: Mutant Huntingtin Protein Aggregation
    description: Expanded HTT generates a polyglutamine-expanded huntingtin species that misfolds and accumulates in oligomers, fibrils, and inclusions.
    hypothesis_groups:
    - canonical_toxic_gain_of_function
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:25336039
      reference_title: "Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions.
      explanation: Directly links pathogenic polyglutamine expansion to the aggregation-prone mutant huntingtin species modeled in the canonical HD pathway.
  - target: Transcriptional Dysregulation
    description: The expanded HTT allele alters neuronal gene expression through mutant huntingtin interactions with transcriptional regulators.
    hypothesis_groups:
    - canonical_toxic_gain_of_function
    - canonical_transcriptional_dysregulation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - nuclear mutant huntingtin
    - disrupted Sp1/CBP/REST-NRSF interactions
    evidence:
    - reference: PMID:11839795
      reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
      explanation: Supports the link from mutant HTT to transcriptional repression through a defined intermediate interaction with Sp1.
  - target: Excitotoxicity
    description: The expanded HTT allele increases vulnerability to NMDAR-driven glutamatergic injury in striatal medium spiny neurons.
    hypothesis_groups:
    - alternative_excitotoxicity
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - altered NMDAR function
    - corticostriatal glutamatergic stress
    evidence:
    - reference: PMID:19279257
      reference_title: "In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD.
      explanation: Connects mutant HTT to the excitotoxicity model through experimentally supported interactions with NMDAR signaling.
- name: Mutant Huntingtin Protein Aggregation
  description: Aggregates of mutant huntingtin protein lead to neuronal dysfunction and death, particularly in the striatum and cerebral cortex.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  evidence:
  - reference: PMID:35319359
    reference_title: "A Review On Huntington Protein: Insight Into Protein Aggregation and Therapeutic Interventions."
    supports: SUPPORT
    snippet: Pathogenesis of HD involves cleavage of the huntingtin protein followed by the neuronal accumulation of its aggregated form.
    explanation: The literature supports that the pathogenesis of Huntington's Disease involves the accumulation of aggregated mutant huntingtin protein, leading to neuronal dysfunction and death.
  - reference: PMID:12657365
    reference_title: "Apoptosis in Huntington's disease."
    supports: SUPPORT
    snippet: The initial and primary target of degeneration in HD is the striatal medium spiny GABAergic neuron, and by end stages of the disease up to 95% of these neurons are lost.
    explanation: This reference supports the statement by highlighting the primary degeneration of neurons in the striatum due to Huntington's Disease.
  - reference: PMID:31813995
    reference_title: "Bim contributes to the progression of Huntington's disease-associated phenotypes."
    supports: SUPPORT
    snippet: Mutant HTT (mHTT) toxicity is caused by its aggregation/oligomerization. The striatum is the most vulnerable region, although all brain regions undergo neuronal degeneration in the disease.
    explanation: This literature supports the statement by confirming that mutant huntingtin protein aggregation leads to neurotoxicity, particularly in the striatum.
  - reference: PMID:23423362
    reference_title: "Role of cerebral cortex in the neuropathology of Huntington's disease."
    supports: SUPPORT
    snippet: Evaluation of postmortem HD tissue indicates that the most prominent cell loss occurs in cerebral cortex and striatum, forebrain regions in which cortical pyramidal neurons (CPNs) and striatal medium spiny neurons (MSNs) are the most affected.
    explanation: This reference supports the statement by indicating significant neuronal loss in the striatum and cerebral cortex in Huntington's Disease.
  - reference: PMID:24048953
    reference_title: "Large Animal Models of Huntington's Disease."
    supports: SUPPORT
    snippet: Huntington's disease is caused by the expansion of a polyglutamine repeat (>37 glutamines) in the disease protein huntingtin, which results in preferential neuronal loss in distinct brain regions.
    explanation: The literature supports the statement by confirming that mutant huntingtin protein causes neuronal loss in specific brain regions, including the striatum and cerebral cortex.
- name: Excitotoxicity
  description: Overactivation of glutamate receptors leading to neuronal damage.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  - preferred_term: excitatory postsynaptic potential
    term:
      id: GO:0060079
      label: excitatory postsynaptic potential
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:38776957
    reference_title: "Single nuclei RNA-seq reveals a medium spiny neuron glutamate excitotoxicity signature prior to the onset of neuronal death in an ovine Huntington's disease model."
    supports: SUPPORT
    snippet: We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD.
    explanation: The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.
  - reference: PMID:1464368
    reference_title: "Mechanisms of excitotoxicity in neurologic diseases."
    supports: SUPPORT
    snippet: Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases.
    explanation: This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.
  - reference: PMID:7590394
    reference_title: "Elevated extracellular glutamate levels increased the formation of hydroxyl radical in the striatum of anesthetized rat."
    supports: SUPPORT
    snippet: Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA.
    explanation: The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.
  - reference: PMID:19805493
    reference_title: "Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity."
    supports: SUPPORT
    snippet: Induction of striatal excitotoxicity in CB(2) receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration.
    explanation: This study shows that excitotoxicity induced in the striatum leads to medium spiny neuron degeneration, supporting the idea of excitotoxicity causing neuronal damage in Huntington's Disease.
- name: Mitochondrial Dysfunction
  description: Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:19622387
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death.
    explanation: Supports the pathophysiology entry by directly linking mitochondrial dysfunction in HD to compromised energy metabolism, oxidative damage, and neuronal death.
  - reference: PMID:23602910
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
    explanation: Supports the mitochondrial dysfunction mechanism by connecting impaired PGC-1alpha activity to defective mitochondrial biogenesis, metabolism, and antioxidant defense in HD.
- name: Neuroinflammation
  description: Activation of microglia and astrocytes with neuroinflammatory responses occurring early in disease progression, contributing to neurodegeneration.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
- name: D2 Receptor Medium Spiny Neuron Selective Vulnerability
  description: D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
- name: Transcriptional Dysregulation
  description: Mutant huntingtin disrupts transcriptional regulation through sequestration of transcription factors including Sp1, CBP, and REST/NRSF, leading to widespread downregulation of neuronal genes including BDNF.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
  evidence:
  - reference: PMID:11839795
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin.
    explanation: In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
  - reference: PMID:11839795
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
    explanation: Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
  - reference: PMID:11264541
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
  - reference: PMID:11264541
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD transgenic mice confirming CBP sequestration into polyglutamine aggregates in vivo.
  - reference: PMID:11264541
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: Human HD postmortem brain tissue showing CBP depletion and sequestration into polyglutamine aggregates.
  - reference: PMID:12881722
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease.
    explanation: Human postmortem brain data showing aberrant nuclear REST/NRSF accumulation and reduced huntingtin-REST/NRSF interaction in HD.
  - reference: PMID:12881722
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease.
    explanation: Mouse model data confirming loss of NRSE-controlled gene expression in HD, corroborating the REST/NRSF dysregulation mechanism.
  - reference: PMID:12881722
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE.
    explanation: Cell-based experiments showing wild-type huntingtin sequesters REST/NRSF in the cytoplasm to permit BDNF transcription, a function lost with the mutant protein.
  downstream:
  - target: Mitochondrial Dysfunction
    description: Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure.
    hypothesis_groups:
    - canonical_transcriptional_dysregulation
    - canonical_mitochondrial_bioenergetic_failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced PGC-1alpha activity
    - impaired mitochondrial biogenesis and antioxidant defense
    evidence:
    - reference: PMID:23602910
      reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
      explanation: Provides the missing causal bridge from transcriptional dysregulation to mitochondrial failure via impaired PGC-1alpha programs.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_toxic_gain_of_function
  hypothesis_label: Toxic Gain-of-Function (Polyglutamine Aggregation)
  status: CANONICAL
  description: >
    The expanded polyglutamine tract in mutant huntingtin confers a toxic
    gain-of-function through protein misfolding, oligomerization, and aggregation
    into inclusion bodies. This is the widely accepted primary disease mechanism,
    with polyQ expansion beyond the pathogenic threshold (~36 repeats) driving
    neurodegeneration predominantly in the striatum.
  evidence:
  - reference: PMID:22180703
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum.
    explanation: Explicitly names the toxic gain-of-function phenotype as the consequence of polyQ expansion and links it to striatal neurodegeneration.
  - reference: PMID:25336039
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions.
    explanation: Directly states the toxic gain-of-function framing and details the aggregation cascade from proteolysis through misfolding to inclusion body formation.
- hypothesis_group_id: canonical_transcriptional_dysregulation
  hypothesis_label: Transcriptional Dysregulation
  status: CANONICAL
  description: >
    Mutant huntingtin disrupts transcriptional regulation by sequestering key
    transcription factors and co-activators (Sp1, CBP, REST/NRSF), leading to
    widespread downregulation of neuronal survival genes including BDNF. This
    is a canonical downstream mechanistic layer in HD, linking mutant huntingtin
    protein interactions to loss of neuronal maintenance programs.
  evidence:
  - reference: PMID:11839795
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin.
    explanation: In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
  - reference: PMID:11839795
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
    explanation: Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
  - reference: PMID:11264541
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
  - reference: PMID:11264541
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD transgenic mice confirming CBP sequestration into polyglutamine aggregates in vivo.
  - reference: PMID:11264541
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: Human HD postmortem brain tissue showing CBP depletion and sequestration into polyglutamine aggregates.
  - reference: PMID:12881722
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease.
    explanation: Human postmortem brain data showing aberrant nuclear REST/NRSF accumulation and reduced huntingtin-REST/NRSF interaction in HD.
  - reference: PMID:12881722
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease.
    explanation: Mouse model data confirming loss of NRSE-controlled gene expression in HD, corroborating the REST/NRSF dysregulation mechanism.
  - reference: PMID:12881722
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE.
    explanation: Cell-based experiments showing wild-type huntingtin sequesters REST/NRSF in the cytoplasm to permit BDNF transcription, a function lost with the mutant protein.
- hypothesis_group_id: canonical_mitochondrial_bioenergetic_failure
  hypothesis_label: Mitochondrial Dysfunction and Bioenergetic Failure
  status: CANONICAL
  description: >
    Mutant huntingtin impairs mitochondrial function through reduced oxidative
    phosphorylation complex activity, disrupted calcium homeostasis, and
    transcriptional repression of PGC-1alpha. This is a canonical convergent
    mechanism in HD that links transcriptional dysregulation and mutant huntingtin
    stress to bioenergetic failure, oxidative damage, and neuronal death,
    particularly in energy-demanding striatal medium spiny neurons.
  evidence:
  - reference: PMID:19622387
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death.
    explanation: Frames mitochondrial dysfunction as a key pathogenic mechanism linking compromised energy metabolism and oxidative damage to neuronal death.
  - reference: PMID:23602910
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
    explanation: Links PGC-1alpha impairment to mitochondrial dysfunction in HD, connecting transcriptional dysregulation of mitochondrial biogenesis genes to bioenergetic failure.
- hypothesis_group_id: alternative_excitotoxicity
  hypothesis_label: NMDA Receptor-Mediated Excitotoxicity
  status: ALTERNATIVE
  description: >
    Historical but still supported superimposed model proposing that mutant
    huntingtin and corticostriatal circuit dysfunction enhance NMDA receptor-mediated
    excitotoxicity in striatal medium spiny neurons. This hypothesis is best viewed
    as a selective-vulnerability amplifier rather than the sole initiating lesion.
  evidence:
  - reference: PMID:17188796
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Many lines of evidence support a role for neuronal damage arising as a result of excessive activation of glutamate receptors by excitatory amino acids in the pathogenesis of Huntington disease. The N-methyl-d-aspartate subclass of ionotropic glutamate receptors (NMDARs) is more selective and effective than the other subclasses in mediating this damage.
    explanation: Comprehensive review establishing NMDAR-mediated excitotoxicity as a key pathogenic mechanism in HD with evidence from human tissue, animal models, and cell-based systems.
  - reference: PMID:19279257
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This is the first direct in vivo evidence of NR2B-NMDAR-mediated excitotoxicity in the context of HD. Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD.
    explanation: Provides the first direct in vivo genetic evidence for the excitotoxicity hypothesis by showing exacerbated striatal neurodegeneration when NR2B-NMDAR subunits are overexpressed in an HD mouse model.
phenotypes:
- name: Chorea
  evidence:
  - reference: PMID:24176425
    reference_title: "Clinical neurogenetics: huntington disease."
    supports: SUPPORT
    snippet: Huntington disease (HD) is an autosomal dominant, adult-onset, progressive neurodegenerative disease characterized by the triad of abnormal movements (typically chorea), cognitive impairment, and psychiatric problems.
    explanation: The reference clearly states that chorea is a characteristic abnormal movement in Huntington's Disease.
  - reference: PMID:36049455
    reference_title: "Chorea: An Update on Genetics."
    supports: SUPPORT
    snippet: Chorea is one of the major manifestations of Huntington's disease.
    explanation: This reference confirms that chorea is a major manifestation of Huntington's Disease.
  - reference: PMID:31707371
    reference_title: "Awareness of Chorea in Huntington's Disease."
    supports: SUPPORT
    snippet: 'BACKGROUND: Anosognosia, or unawareness of illness of deficits, has been observed in Huntington''s disease (HD) in relation to motor and cognitive signs and symptoms. Most studies of awareness in HD have used self-report questionnaire methodology rather than asking patients to report on their symptoms in real-time. The two studies in which patients were asked about their chorea in real-time had small sample sizes and only examined patients early in disease progression.'
    explanation: The reference mentions chorea in the context of Huntington's Disease, supporting the statement.
  - reference: PMID:6446233
    reference_title: "Huntington's disease."
    supports: SUPPORT
    snippet: Huntington's disease (chorea) is characterized by abnormal movements and dementia.
    explanation: This reference directly associates Huntington's Disease with chorea.
  - reference: PMID:32699773
    reference_title: "Drug-Resistant Epilepsy in Children with Juvenile Huntington's Disease: A Challenging Case and Brief Review."
    supports: SUPPORT
    snippet: Huntington's Disease (HD) is an autosomal dominant neurodegenerative disorder with a progressive decline in cognitive, motor, and psychological function. Chorea tends to be the most common associated movement disorder, although other variants of several abnormal movements are also seen.
    explanation: The reference states that chorea is the most common associated movement disorder in Huntington's Disease.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
- name: Dystonia
  description: Involuntary muscle contractions causing twisting and repetitive movements or abnormal postures.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
- name: Bradykinesia
  description: Slowness of movement, a common motor symptom in Huntington's Disease.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
- name: Cognitive Impairment
  description: Progressive decline in cognitive function affecting memory, executive function, and other cognitive domains.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
- name: Depression
  description: Mood disorder characterized by persistent sadness and loss of interest, common psychiatric manifestation in HD.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
- name: Weight Loss
  description: Progressive unintentional weight loss due to metabolic changes and systemic effects.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- name: Dysphagia
  description: Difficulty swallowing that occurs in later stages of the disease.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
biochemical:
- name: Elevated Neuronal Inclusions
  presence: Positive
  notes: Aggregates of mutant huntingtin protein found in neurons.
  evidence:
  - reference: PMID:22200539
    reference_title: "Protein aggregates in Huntington's disease."
    supports: SUPPORT
    snippet: Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs).
    explanation: The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.
  - reference: PMID:38810948
    reference_title: "Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington's disease cases."
    supports: SUPPORT
    snippet: We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients.
    explanation: The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.
  - reference: PMID:19172113
    reference_title: "Aggregation of expanded huntingtin in the brains of patients with Huntington disease."
    supports: SUPPORT
    snippet: It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species.
    explanation: The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.
  - reference: PMID:27886014
    reference_title: "Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease."
    supports: SUPPORT
    snippet: Using highly sensitive immunohistochemical methods we have detected the appearance of diffuse aggregates during embryonic development in the R6/2 and YAC128 mouse models of HD.
    explanation: The study observes the formation of aggregates in neuronal cells during embryonic development in mouse models of HD, supporting the statement.
genetic:
- name: HTT
  association: Pathogenic CAG Repeat Expansion
  notes: Primary causal gene encoding huntingtin protein; CAG repeat expansion leads to polyglutamine tract elongation.
  inheritance:
  - name: Autosomal Dominant
  evidence:
  - reference: PMID:27188817
    reference_title: "Huntington disease."
    supports: SUPPORT
    snippet: Huntington disease is devastating to patients and their families - with autosomal dominant inheritance... The disease is caused by an expanded CAG trinucleotide repeat (of variable length) in HTT, the gene that encodes the protein huntingtin.
    explanation: The literature explicitly states that Huntington's disease is caused by an expanded CAG trinucleotide repeat in the HTT gene and is inherited in an autosomal dominant manner.
  - reference: PMID:33579864
    reference_title: "Approaches to Sequence the HTT CAG Repeat Expansion and Quantify Repeat Length Variation."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the expansion of the HTT CAG repeat.
    explanation: This reference confirms that Huntington's disease is caused by the expansion of the HTT CAG repeat and follows an autosomal dominant inheritance pattern.
  - reference: PMID:31820322
    reference_title: "Late-onset Huntington's disease with 40-42 CAG expansion."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene.
    explanation: This source supports the statement by indicating that Huntington's disease is an autosomal dominant disorder caused by a CAG expansion in the HTT gene.
  - reference: PMID:37863037
    reference_title: "HD and SCA1: Tales from two 30-year journeys since gene discovery."
    supports: SUPPORT
    snippet: Among the CAG/polyQ repeat diseases are Huntington's disease (HD) and spinocerebellar ataxia type 1 (SCA1), in which the expansions are within widely expressed proteins. Although both HD and SCA1 are autosomal dominantly inherited...
    explanation: This reference supports the statement by confirming that Huntington's disease is among the CAG repeat diseases and is autosomal dominantly inherited.
  - reference: PMID:33579866
    reference_title: "What is the Pathogenic CAG Expansion Length in Huntington's Disease?"
    supports: SUPPORT
    snippet: Huntington's disease (HD) (OMIM 143100) is caused by an expanded CAG repeat tract in the HTT gene. The inherited CAG length is known to expand further in somatic and germline cells in HD subjects.
    explanation: This source supports the statement by confirming that Huntington's disease is caused by an expanded CAG repeat in the HTT gene and follows an autosomal dominant inheritance pattern.
  - reference: PMID:36352624
    reference_title: "Complexities in Genetic Counseling and Testing of Huntington's Disease: A Perspective from India."
    supports: SUPPORT
    snippet: Huntington's Disease (HD) is an autosomal dominant, progressive neuropsychiatric illness caused by CAG repeat expansion.
    explanation: This reference supports the statement by confirming that Huntington's disease is an autosomal dominant disorder caused by CAG repeat expansion.
  - reference: PMID:31263285
    reference_title: "Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the huntingtin gene (HTT)...
    explanation: This source supports the statement by confirming that Huntington's disease is caused by a CAG trinucleotide expansion in the HTT gene and follows an autosomal dominant inheritance pattern.
  - reference: PMID:31491822
    reference_title: "Cortical neurodevelopment in pre-manifest Huntington's disease."
    supports: SUPPORT
    snippet: The expression of the HTT CAG repeat expansion mutation causes neurodegeneration in Huntington's disease (HD).
    explanation: This reference supports the statement by confirming that the HTT CAG repeat expansion causes neurodegeneration in Huntington's disease.
  - reference: PMID:26439718
    reference_title: "Huntington Disease: Molecular Diagnostics Approach."
    supports: SUPPORT
    snippet: Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in the first exon of the Huntingtin (HTT) gene.
    explanation: This source supports the statement by confirming that Huntington's disease is caused by the expansion of a CAG trinucleotide repeat in the HTT gene.
  - reference: PMID:28832564
    reference_title: "Haplotype-based stratification of Huntington's disease."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by expansion of a CAG trinucleotide repeat in HTT...
    explanation: This reference supports the statement by confirming that Huntington's disease is caused by the expansion of a CAG trinucleotide repeat in the HTT gene and is autosomal dominant.
  - reference: CGGV:assertion_617c18ee-9476-4bc0-b403-20bc55150c7c-2021-11-08T193955.489Z
    reference_title: "HTT / Huntington disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HTT | HGNC:4851 | Huntington disease | MONDO:0007739 | AD | Definitive"
    explanation: ClinGen classifies the HTT-Huntington disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: MSH3
  association: Genetic Modifier
  notes: DNA mismatch repair gene; modulates somatic CAG instability and influences age at onset via somatic expansion.
- name: MLH1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; drives somatic CAG expansion and significantly affects disease onset age and progression.
- name: PMS1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: PMS2
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: LIG1
  association: Genetic Modifier
  notes: DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG instability.
- name: PPARGC1A
  association: Pathophysiological Role
  notes: PGC-1alpha gene; reduced expression contributes to bioenergetic failure and mitochondrial dysfunction in HD.
- name: SLC1A2
  association: Pathophysiological Role
  notes: EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity through reduced glutamate clearance.
- name: BDNF
  association: Pathophysiological Role
  notes: Brain-derived neurotrophic factor; impaired trophic signaling and transport from cortex to striatum contributes to neuronal vulnerability.
- name: NTRK2
  association: Pathophysiological Role
  notes: TrkB receptor gene; mediates BDNF signaling; impaired function contributes to reduced trophic support.
- name: DRD1
  association: Pathophysiological Role
  notes: Dopamine D1 receptor; marker of direct pathway medium spiny neurons.
- name: DRD2
  association: Pathophysiological Role
  notes: Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which show earlier vulnerability and greater CAG instability.
- name: SQSTM1
  association: Pathophysiological Role
  notes: p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal pathway dysfunction.
environmental:
- name: None Applicable
  evidence:
  - reference: PMID:20591965
    reference_title: "Huntington's disease."
    supports: NO_EVIDENCE
    snippet: Huntington's disease.
    explanation: The provided reference does not mention anything about 'None Applicable' in relation to Huntington's Disease.
  - reference: PMID:1535663
    reference_title: "Huntington's disease and the ethics of genetic prediction."
    supports: NO_EVIDENCE
    snippet: What ethical justification can be found for informing a person that he or she will later develop a lethal disease for which no therapy is available?
    explanation: The provided reference discusses the ethics of genetic prediction and testing for Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:29856024
    reference_title: "Nonhuman Primate Models of Huntington's Disease and Their Application in Translational Research."
    supports: NO_EVIDENCE
    snippet: Huntington's disease (HD) is a monogenic, autosomal dominant inherited fatal disease that affects 1 in 10,000 people worldwide.
    explanation: The provided reference discusses nonhuman primate models for Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:18414297
    reference_title: "Huntington's disease. Part 3: family aspects of HD."
    supports: NO_EVIDENCE
    snippet: Research into the experience of the Huntington's disease (HD) family caregiver has established that HD carers experience a number of unique obstacles within their caregiving role.
    explanation: The provided reference discusses the family aspects of Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:18846148
    reference_title: "[Huntington's disease]."
    supports: NO_EVIDENCE
    snippet: Huntington's disease is an autosomal dominant slowly degenerative apoptotic condition in CNS, in particular in striatum.
    explanation: The provided reference discusses the clinical and genetic aspects of Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:34842303
    reference_title: "An MDS Evidence-Based Review on Treatments for Huntington's Disease."
    supports: NO_EVIDENCE
    snippet: Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations.
    explanation: The provided reference discusses treatments for Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:26569646
    reference_title: "[Periodontitis determining the onset and progression of Huntington's disease: review of the literature]."
    supports: NO_EVIDENCE
    snippet: Huntington's disease is a neurodegenerative disorder caused by the expansion of a CAG triplet in the huntingtin gene.
    explanation: The provided reference discusses the role of periodontitis in Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:25164859
    reference_title: "Huntington's disease: a field on the move. Introduction."
    supports: NO_EVIDENCE
    snippet: 'Huntington''s disease: a field on the move. Introduction.'
    explanation: The provided reference is an introduction to Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:29737569
    reference_title: "Huntington's disease: Current and future therapeutic prospects."
    supports: NO_EVIDENCE
    snippet: Huntington's disease is a progressive neurodegenerative disorder for which therapies are woefully inadequate and do not prevent inevitable progression.
    explanation: The provided reference discusses current and future therapeutic prospects for Huntington's Disease but does not mention 'None Applicable' as a value.
  - reference: PMID:32179957
    reference_title: "[Gene-selective treatment approaches for Huntington's disease]."
    supports: NO_EVIDENCE
    snippet: In Germany at least 8000 and probably up to ca. 14,000 people currently suffer from clinically manifest Huntington's disease (HD).
    explanation: The provided reference discusses gene-selective treatment approaches for Huntington's Disease but does not mention 'None Applicable' as a value.
animal_models:
- species: Mouse
  genotype: R6/2 Transgenic
  description: Mice expressing human mutant huntingtin with expanded CAG repeats used to model motor and cognitive deficits.
  associated_phenotypes:
  - Progressive Motor Dysfunction
  - Cognitive Impairment
  - Weight Loss
  evidence:
  - reference: PMID:18638556
    reference_title: "Rodent genetic models of Huntington disease."
    supports: SUPPORT
    snippet: Huntington disease (HD) is a dominantly inherited human neurodegenerative disorder characterized by motor deficits, cognitive impairment, and psychiatric symptoms leading to inexorable decline and death. Since the identification of the huntingtin gene and the characteristic expanded CAG repeat/polyglutamine mutation, multiple murine genetic models and one rat genetic model have been generated.
    explanation: This reference supports the statement as it describes Huntington's disease as involving motor deficits and cognitive impairment, and mentions the use of murine genetic models, including transgenic ones with expanded CAG repeats like the R6/2 model.
  - reference: PMID:35007790
    reference_title: "Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice."
    supports: SUPPORT
    snippet: We used the R6/2 and BACHD mouse models that express different lengths of mutant HTT to develop lean- and obese phenotypes, respectively. We utilized adeno-associated viral vectors to overexpress either mutant or wild-type HTT in the hypothalamus of R6/2, BACHD, and their wild-type littermates. The metabolic phenotype was assessed by body weight measurements over time and body composition analysis using dual-energy x-ray absorptiometry at the endpoint.
    explanation: This reference supports the statement by describing the use of R6/2 mice, which express mutant HTT, to study metabolic phenotypes including weight changes, indicating weight loss as part of the disease phenotype.
  - reference: PMID:29856017
    reference_title: "Motor Assessment in Huntington's Disease Mice."
    supports: SUPPORT
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the statement by confirming that motor deficits are a characteristic consequence of genetic models of Huntington's disease, including those with polyglutamine expansion such as the R6/2 model.
  - reference: PMID:31868674
    reference_title: "Correlations Between Mutant Huntingtin Aggregates and Behavioral Changes in R6/1 Mice."
    supports: SUPPORT
    snippet: 'Huntington''s disease (HD) is a neurodegenerative disorder caused by the expansion of the trinucleotide CAG in the HD gene. While the presence of nuclear aggregates of mutant huntingtin (mHtt) in neurons is a hallmark of HD, the reason behind its toxicity remains elusive. OBJECTIVE: The present study was conducted to assess a correlation between the number of mHtt aggregates and the severity of HD symptoms in R6/1 mice.'
    explanation: This reference supports the statement by describing the use of R6/1 mice, a similar model to R6/2, to study the correlation between mutant huntingtin aggregates and the severity of HD symptoms, including motor and cognitive deficits.
  - reference: PMID:15525658
    reference_title: "Orexin loss in Huntington's disease."
    supports: SUPPORT
    snippet: We describe for the first time a dramatic atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found a significant atrophy and loss of orexin neurons in Huntington patients.
    explanation: This reference supports the statement by describing the use of R6/2 mice to model Huntington's disease, noting significant neuronal changes that correlate with the disease phenotype.
diagnosis:
- name: Genetic Testing for HTT CAG Expansion
  presence: Positive
  notes: Confirmation of diagnosis through DNA analysis.
  evidence:
  - reference: PMID:26439718
    reference_title: "Huntington Disease: Molecular Diagnostics Approach."
    supports: SUPPORT
    snippet: Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in the first exon of the Huntingtin (HTT) gene. Molecular testing of Huntington disease for diagnostic confirmation and disease prediction requires detection of the CAG repeat expansion.
    explanation: The literature confirms that genetic testing for HTT CAG expansion is used for the diagnostic confirmation of Huntington's Disease.
  - reference: PMID:23390178
    reference_title: "The challenge of juvenile Huntington disease: to test or not to test."
    supports: SUPPORT
    snippet: We analyzed the clinical and genetic characteristics of 76 juvenile-onset patients referred consecutively for HD genetic testing over a 16-year period. ... All expanded cases had a family history of genetically confirmed HD compared to only 13.5% of unexpanded cases (p = 0.000).
    explanation: This study supports the use of genetic testing for confirming the diagnosis of Huntington's Disease by identifying the CAG expansion.
  - reference: PMID:31820322
    reference_title: "Late-onset Huntington's disease with 40-42 CAG expansion."
    supports: SUPPORT
    snippet: Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene.
    explanation: This reference supports the statement that Huntington's Disease is confirmed through genetic testing for HTT CAG expansion.
  - reference: PMID:28947110
    reference_title: "Genetic testing for Huntington disease."
    supports: SUPPORT
    snippet: The gene for HD was found in 1993, allowing for direct gene testing for the mutant HTT allele.
    explanation: The discovery of the HD gene allows for direct genetic testing to confirm the presence of HTT CAG expansion, supporting the statement.
- name: Neurological Examination
  notes: Assessment of motor disturbances, cognitive function, and psychiatric symptoms.
  evidence:
  - reference: PMID:29856017
    reference_title: "Motor Assessment in Huntington's Disease Mice."
    supports: SUPPORT
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the assessment of motor disturbances in Huntington's Disease.
  - reference: PMID:29278291
    reference_title: "Rating scales for cognition in Huntington's disease: Critique and recommendations."
    supports: SUPPORT
    snippet: Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum.
    explanation: This reference supports the assessment of cognitive function in Huntington's Disease.
  - reference: PMID:30012004
    reference_title: "Huntington's disease: Neuropsychiatric manifestations of Huntington's disease."
    supports: SUPPORT
    snippet: This clinical update review focuses on the common neuropsychiatric manifestations in HD, and outlines and evaluates the various neuropsychiatric facets of HD, including the aetiology, symptoms and diagnosis.
    explanation: This reference supports the assessment of psychiatric symptoms in Huntington's Disease.
  - reference: PMID:31922295
    reference_title: "Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease."
    supports: SUPPORT
    snippet: To determine the relationships between the motor phenotype and the presence of specific neuropsychiatric and neuropsychological disorders in patients with early motor-manifest Huntington's disease.
    explanation: This reference supports the assessment of motor disturbances, cognitive function, and psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36450478
    reference_title: "Impairments to executive function in emerging adults with Huntington disease."
    supports: SUPPORT
    snippet: Recent reports highlight the onset of cognitive and psychiatric symptoms before motor manifestations.
    explanation: This reference supports the assessment of cognitive function and psychiatric symptoms in Huntington's Disease.
treatments:
- name: Tetrabenazine
  role: Symptomatic
  description: Used to manage chorea by depleting dopamine.
  evidence:
  - reference: PMID:24366610
    reference_title: "Treatment of Huntington's disease."
    supports: SUPPORT
    snippet: Tetrabenazine is a dopamine-depleting agent that may be one of the more effective agents for reducing chorea, although it has a risk of potentially serious adverse effects.
    explanation: This reference confirms that tetrabenazine is used to manage chorea in Huntington's Disease by depleting dopamine.
  - reference: PMID:20869622
    reference_title: "Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders."
    supports: SUPPORT
    snippet: Tetrabenazine (TBZ) is a monoamine-depleting agent initially studied in the 1950s and currently approved by the US Food and Drug Administration for the treatment of chorea in Huntington's disease.
    explanation: This reference confirms that tetrabenazine depletes monoamines, including dopamine, to manage chorea in Huntington's Disease.
  - reference: PMID:20442355
    reference_title: "Role of tetrabenazine for Huntington's disease-associated chorea."
    supports: SUPPORT
    snippet: Tetrabenazine binds reversibly to the type 2 vesicular monoamine transporters and has been shown to inhibit monoamine uptake in presynaptic vesicles, resulting in monoamine depletion.
    explanation: This reference supports that tetrabenazine depletes dopamine to manage chorea in Huntington's Disease.
  - reference: PMID:27819145
    reference_title: "Dopamine depleters in the treatment of hyperkinetic movement disorders."
    supports: SUPPORT
    snippet: Since the approval of tetrabenazine, the classic VMAT2 inhibitor, in the treatment of chorea associated with Huntington disease (HD)...
    explanation: This reference confirms that tetrabenazine, a VMAT2 inhibitor, is used to treat chorea in Huntington's Disease by depleting dopamine.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: tetrabenazine
      term:
        id: CHEBI:9467
        label: tetrabenazine
- name: Antipsychotic Medications
  role: Symptomatic
  description: Used for psychiatric symptoms like irritability and agitation.
  evidence:
  - reference: PMID:27534434
    reference_title: "Antipsychotic drugs in Huntington's disease."
    supports: SUPPORT
    snippet: In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms...
    explanation: The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.
  - reference: PMID:16383221
    reference_title: "Behavioral symptoms associated with Huntington's disease."
    supports: SUPPORT
    snippet: According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy.
    explanation: The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36496108
    reference_title: "Neuropharmacological effect of risperidone: From chemistry to medicine."
    supports: SUPPORT
    snippet: Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease...
    explanation: Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  role: Symptomatic
  description: Used to manage depression.
  evidence:
  - reference: PMID:18394562
    reference_title: "Symptomatic treatment of Huntington disease."
    supports: SUPPORT
    snippet: Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants...
    explanation: The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.
  - reference: PMID:22119091
    reference_title: "Suicidality in Huntington's disease."
    supports: SUPPORT
    snippet: Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)...
    explanation: The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Physical Therapy
  role: Supportive
  description: Helps maintain mobility and function.
  evidence:
  - reference: PMID:31907286
    reference_title: "Clinical recommendations to guide physical therapy practice for Huntington disease."
    supports: SUPPORT
    snippet: There is strong evidence to support physical therapy interventions to improve fitness, motor function, and gait in persons with HD.
    explanation: The review provides strong evidence that physical therapy interventions improve fitness, motor function, and gait in people with Huntington's Disease, supporting the statement that physical therapy helps maintain mobility and function.
  - reference: PMID:31177235
    reference_title: "Ancillary Service Utilization and Impact in Huntington's Disease."
    supports: SUPPORT
    snippet: Prior Huntington''s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life.
    explanation: The study indicates that ancillary services, which include physical therapy, improve motor symptoms in HD patients, supporting the statement that physical therapy helps maintain mobility and function.
  - reference: PMID:25062860
    reference_title: "Optimising mobility outcome measures in Huntington's disease."
    supports: SUPPORT
    snippet: TUG (beta 0.46, CI 0.20-3.47), BBS (beta -0.35, CI -2.10-0.14), and TMT (beta -0.45, CI -3.14-0.64) were good disease-specific mobility measures.
    explanation: The study identifies specific mobility measures that are effective for assessing and optimizing mobility in HD patients, supporting the statement that physical therapy helps maintain mobility and function.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Speech Therapy
  role: Supportive
  description: Helps manage dysarthria and dysphagia.
  evidence:
  - reference: PMID:28983422
    reference_title: "Speech-Language Pathology Evaluation and Management of Hyperkinetic Disorders Affecting Speech and Swallowing Function."
    supports: PARTIAL
    snippet: SLPs play an important role in the evaluation and management of dysarthria and dysphagia.
    explanation: The literature indicates that speech-language pathologists (SLPs) play a significant role in managing dysarthria and dysphagia in patients with hyperkinetic disorders, including Huntington's Disease. However, it does not explicitly state that speech therapy helps manage these conditions in HD specifically.
  - reference: PMID:33577706
    reference_title: "Speech and language difficulties in Huntington's disease: A qualitative study of patients' and professional caregivers' experiences."
    supports: PARTIAL
    snippet: Findings shed a light on everyday communication challenges faced by people with HD and their professional caregivers, and the lack of implementation of communication aids in this group.
    explanation: The literature highlights the importance of including speech and language therapists in the care of HD patients, indicating a supportive role. However, it does not provide explicit evidence that speech therapy directly helps manage dysarthria and dysphagia in HD.
  - reference: PMID:31989345
    reference_title: "Management of dysphagia in Huntington's disease: a descriptive review."
    supports: NO_EVIDENCE
    snippet: The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature.
    explanation: The literature states that the impact of rehabilitative treatments, including speech therapy, on dysphagia in HD has been minimally studied, providing no clear evidence of its efficacy.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Occupational Therapy
  role: Supportive
  description: Assists with daily living activities.
  evidence:
  - reference: PMID:28947114
    reference_title: "The role of rehabilitation therapy in Huntington disease."
    supports: PARTIAL
    snippet: Lifestyle factors, such as activity level and exercise, as well as specific motor training may be helpful in managing the functional sequelae of HD and possibly slowing disease progression.
    explanation: The literature suggests that rehabilitation interventions, including motor training, can help manage functional abilities in HD, which implies a supportive role in daily living activities. However, it does not explicitly mention occupational therapy or daily living activities directly.
  - reference: PMID:36055643
    reference_title: "Informal care in Huntington's disease: Assessment of objective-subjective burden and its associated risk and protective factors."
    supports: PARTIAL
    snippet: This objective burden increased with higher functional loss of the HD individual and with more severe cognitive-behavioral disorders.
    explanation: This study discusses the burden on informal caregivers and the functional loss in HD individuals, indicating a need for supportive roles, which could include occupational therapy. However, it does not explicitly mention occupational therapy.
  - reference: PMID:31177235
    reference_title: "Ancillary Service Utilization and Impact in Huntington's Disease."
    supports: SUPPORT
    snippet: Prior Huntington's disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear.
    explanation: The literature explicitly mentions that ancillary services, which include occupational therapy, improve various aspects of life for HD patients, indicating a supportive role in daily living activities.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Genetic Counseling
  role: Supportive
  description: Provides information and support regarding inheritance patterns, predictive testing, and family planning for individuals at risk or affected by HD.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
review_notes: Huntington's Disease is a progressive neurodegenerative disorder characterized by a triad of motor, cognitive, and psychiatric symptoms. The genetic basis and impactful phenotypes have been summarized. Further research on therapeutic interventions is ongoing, focusing on disease-modifying treatments.
disease_term:
  preferred_term: Huntington disease
  term:
    id: MONDO:0007739
    label: Huntington disease
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
  - classification_value: neurodegenerative disease
  - classification_value: movement disorder
references:
- reference: DOI:10.21608/rpbs.2025.410003.1392
  title: Molecular and Cellular Insights into Huntington's Disease Pathophysiology
  findings: []
- reference: DOI:10.3389/fncel.2023.1094503
  title: Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington's disease
  findings: []
- reference: DOI:10.3390/biology14020129
  title: 'Advances in Huntington''s Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review'
  findings: []
- reference: DOI:10.3390/genes15060807
  title: 'Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease'
  findings: []
- reference: DOI:10.3390/ijms25073845
  title: 'Huntington''s Disease: Complex Pathogenesis and Therapeutic Strategies'
  findings: []
- reference: DOI:10.3390/ijms252111787
  title: 'Neuroinflammatory Proteins in Huntington''s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications'
  findings: []
📚

References & Deep Research

References

6
DOI:10.21608/rpbs.2025.410003.1392
Molecular and Cellular Insights into Huntington's Disease Pathophysiology
No top-level findings curated for this source.
DOI:10.3389/fncel.2023.1094503
Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington's disease
No top-level findings curated for this source.
DOI:10.3390/biology14020129
Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review
No top-level findings curated for this source.
DOI:10.3390/genes15060807
Beyond CAG Repeats: The Multifaceted Role of Genetics in Huntington Disease
No top-level findings curated for this source.
DOI:10.3390/ijms25073845
Huntington's Disease: Complex Pathogenesis and Therapeutic Strategies
No top-level findings curated for this source.
DOI:10.3390/ijms252111787
Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Huntington's Disease
  • Category: Genetic
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 94

Key Pathophysiology Nodes

  • CAG Repeat Expansion in the HTT Gene
  • Mutant Huntingtin Protein Aggregation
  • Excitotoxicity
  • Mitochondrial Dysfunction
  • Neuroinflammation
  • D2 Receptor Medium Spiny Neuron Selective Vulnerability
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.21608/rpbs.2025.410003.1392
  • DOI:10.3389/fncel.2023.1094503
  • DOI:10.3390/biology14020129
  • DOI:10.3390/genes15060807
  • DOI:10.3390/ijms25073845
  • DOI:10.3390/ijms252111787
Falcon ▸
Pathophysiology Description
Edison Scientific Literature 20 citations 2025-12-15T09:11:22.422104

Pathophysiology Description HD is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion in HTT that encodes an expanded polyglutamine tract in huntingtin. A multi-layered pathobiology is supported by recent work emphasizing: somatic CAG repeat instability (modulated by DNA mismatch repair genes) as a strong driver of onset/progression; selective vulnerability of striatal medium spiny neurons (MSNs) with relative early involvement of D2R MSNs and striosome–matrix axes; corticostriatal excitatory/inhibitory imbalance; mitochondrial dysfunction with bioenergetic deficits and mtDNA instability; stage-dependent autophagy-lysosomal alterations; glial-driven neuroinflammation; RNA-mediated toxicity including exon 1 HTT species; and broader neurovascular and systemic features. “Mutant huntingtin protein (mHTT) misfolding and aggregation … impact transcription, mitochondrial function and autophagy,” and “somatic CAG repeat expansion … occurs in peripheral tissues as well as brain,” underscoring HD as a systemic multi-compartment disease (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6).

1) Core Pathophysiology - Somatic CAG repeat instability: Genetic modifiers in DNA maintenance/repair pathways (e.g., MSH3, MLH1, PMS1, PMS2, LIG1) influence age at onset and progression by modulating somatic expansion of the HTT CAG tract. “CAG repeat expansion is highly unstable … with the striatum and cerebral cortex displaying the highest levels of somatic expansions,” and “Brain somatic CAG instability is associated with an earlier age at onset.” A threshold model posits disease arises when “somatic expansion surpasses a cell-type specific pathological threshold in vulnerable cells” (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 5-7, pengo2024beyondcagrepeats pages 7-8). A complementary review notes “MLH1 drives somatic expansion and significantly affects disease onset age and the course of HD,” and highlights early mitochondrial changes and systemic involvement (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6). - MSN vulnerability and circuit disruption: In knock-in models with cell-type reporters, “we observed an early increase in huntingtin aggregates in D2R-MSNs compared to D1R-MSNs,” with “D2R-MSNs show greater sensitivity to CAG somatic instability” and putative compensatory upregulation of oxidative phosphorylation and translation in D1R-MSNs (unknown journal, 2025; cited DOIs within text; see quotes) (bergonzoni2025exploringcentraland pages 15-20). Regional specificity (caudal > rostral; dorsomedial > ventrolateral) and functional contributors include impaired cortical trophic support (BDNF transport), reduced astrocytic EAAT2-mediated glutamate clearance (excitotoxic stress), early hyperdopaminergic states with dopamine-derived ROS activating JNK/c-Jun, and electrophysiological alterations (increased input resistance, reduced rheobase, depolarized resting potential) in MSNs (unknown journal, 2025; synthesis with references therein) (bergonzoni2025exploringcentraland pages 56-59). - Mitochondrial dysfunction and mtDNA instability: Early and systemic mitochondrial defects are consistently reported. In a broad review, “reduced efficiency of oxidative phosphorylation (OXPHOS) complexes II and III, loss of mitochondrial membrane potential, and diminished aconitase activity” were emphasized, with PGC-1α suppression contributing to bioenergetic failure (Records of Pharmaceutical and Biomedical Sciences, Mar 2025; https://doi.org/10.21608/rpbs.2025.410003.1392) (elgindy2025molecularandcellular pages 2-4). Peripheral mtDNA heteroplasmy expansions correlated with clinical decline over years in large cohorts, supporting mtDNA alterations as biomarkers (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 7-8). - Autophagy-lysosomal pathway: Autophagy-lysosome function is variably competent early but becomes overloaded/inefficient with disease progression, with accumulation of p62/SQSTM1 and lysosomal markers as substrate burden rises; enhancing autophagy is proposed as a therapeutic strategy (IJMS review, Mar 2024; https://doi.org/10.3390/ijms25073845; RPBS, Mar 2025; https://doi.org/10.21608/rpbs.2025.410003.1392) (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4). - Neuroinflammation: “Activation of the immune system and glial cell-mediated neuroinflammatory responses are early pathological features,” implicating microglia, astrocytes, and oligodendrocytes (IJMS, Nov 2024; https://doi.org/10.3390/ijms252111787) (tong2024huntington’sdiseasecomplex pages 4-5). Spatially heterogeneous astrocyte changes and clustering in striatum are observed in models, consistent with regionally patterned gliosis (Frontiers in Cellular Neuroscience, Apr 2023; https://doi.org/10.3389/fncel.2023.1094503) (tong2024huntington’sdiseasecomplex pages 4-5). - RNA/splicing toxicity and exon 1 HTT: Altered splicing produces exon 1 HTT (HTT1a), “the most toxic N-terminal fragment,” with exon 1 species correlating with aggregation and representing a key therapeutic target distinct from full-length HTT (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 7-8). Reviews also note mHTT mRNA toxicity and closer correlation of disease with uninterrupted CAG repeat length in RNA (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6). - Neurovascular/endothelial dysfunction: Emerging literature reframes HD as including neurovascular pathology with impaired neurovascular coupling and BBB changes; lifestyle and systemic mediators likely modulate central pathology (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6).

2) Key Molecular Players - Genes/Proteins (HGNC): HTT (mutant huntingtin); MSH3, MLH1, PMS1, PMS2, LIG1 (MMR modifiers); DRD1, DRD2 (MSN receptors); SLC1A2/EAAT2 (astrocytic glutamate transporter); PPARGC1A/PGC-1α (bioenergetic regulator); BDNF, NTRK2/TrkB (trophic signaling); SQSTM1/p62, LAMP1, CTSD (autophagy-lysosome); AIF1/IBA1, GFAP, OLIG2 (glial markers) (pengo2024beyondcagrepeats pages 5-7, tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4, bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6). - Chemical Entities (CHEBI): Glutamate (excitotoxic stress), dopamine (ROS generation); reactive oxygen species; lipids involved in peroxidation (ferroptosis-related); no specific CHEBI IDs provided in the cited texts; mechanistic context noted above (bergonzoni2025exploringcentraland pages 56-59, elgindy2025molecularandcellular pages 2-4). - Cell Types (CL): Medium spiny neuron (CL:0000548); astrocyte (CL:0000127); microglial cell (CL:0000129); oligodendrocyte (CL:0000131); endothelial cell (CL:0000235) (supported throughout) (tong2024huntington’sdiseasecomplex pages 4-5, bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6). - Anatomical Locations (UBERON): Striatum (UBERON:0001880), cerebral cortex (UBERON:0000955), brain vasculature (UBERON:0001045), skeletal muscle (UBERON:0001134), enteric nervous system (UBERON:0005409) (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6).

3) Biological Processes (for GO annotation) - DNA mismatch repair (GO:0006298) – somatic CAG instability (pengo2024beyondcagrepeats pages 5-7, aqel2025advancesinhuntington’s pages 4-6). - Synaptic transmission and excitatory signaling (GO:0007268; GO:0007215) – corticostriatal dysfunction/excitotoxicity (bergonzoni2025exploringcentraland pages 56-59, tong2024huntington’sdiseasecomplex pages 4-5). - Mitochondrion organization and oxidative phosphorylation (GO:0007005; GO:0006119) – mitochondrial dysfunction (elgindy2025molecularandcellular pages 2-4, pengo2024beyondcagrepeats pages 7-8). - Autophagy and lysosomal organization (GO:0006914; GO:0005764) – ALP status (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4). - Inflammatory response (GO:0006954) – neuroinflammation across glial types (tong2024huntington’sdiseasecomplex pages 4-5). - RNA splicing (GO:0008380) and mRNA metabolism (GO:0016071) – exon 1 HTT, RNA toxicity (pengo2024beyondcagrepeats pages 7-8, aqel2025advancesinhuntington’s pages 4-6). - Neurotrophin receptor signaling (GO:0048011) – BDNF/TrkB (bergonzoni2025exploringcentraland pages 56-59). - Response to oxidative stress (GO:0006979) – ROS and ferroptosis-related stress (elgindy2025molecularandcellular pages 2-4, bergonzoni2025exploringcentraland pages 56-59).

4) Cellular Components - Nucleus and nuclear bodies – aggregation-prone exon 1 HTT, transcriptional dysregulation (pengo2024beyondcagrepeats pages 7-8, tong2024huntington’sdiseasecomplex pages 4-5). - Mitochondria – OXPHOS defects, membrane potential loss, mtDNA instability (elgindy2025molecularandcellular pages 2-4, pengo2024beyondcagrepeats pages 7-8). - Autophagosomes/lysosomes – p62/SQSTM1, LAMP1, CTSD-positive compartments; substrate accumulation at later stages (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4). - Synapses – corticostriatal terminals; EAAT2 at astrocytic membranes; altered MSN excitability (bergonzoni2025exploringcentraland pages 56-59, tong2024huntington’sdiseasecomplex pages 4-5). - Endothelial tight junctions/BBB – emerging dysfunction (aqel2025advancesinhuntington’s pages 4-6).

5) Disease Progression (Sequence of Events) - Inheritance of expanded CAG allele leads to age-dependent somatic CAG expansion in vulnerable cells, particularly striatal MSNs, driven by DNA repair pathways (MMR modifiers) (pengo2024beyondcagrepeats pages 5-7, aqel2025advancesinhuntington’s pages 4-6). - Early mitochondrial dysfunction and bioenergetic stress; transcriptional dysregulation including PGC-1α suppression; early glial activation (elgindy2025molecularandcellular pages 2-4, tong2024huntington’sdiseasecomplex pages 4-5). - Circuit-level stress with reduced EAAT2-mediated glutamate clearance, dopamine-driven ROS, and altered MSN excitability; D2R-MSNs affected earlier than D1R-MSNs; regional gradients (bergonzoni2025exploringcentraland pages 56-59, bergonzoni2025exploringcentraland pages 15-20). - Autophagy-lysosome flux initially compensates but later becomes insufficient with cumulative substrate load (p62/SQSTM1, LAMP changes) (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4). - Progressive neuronal dysfunction and loss in striatum with expanding systemic and neurovascular involvement (aqel2025advancesinhuntington’s pages 4-6).

6) Phenotypic Manifestations and Mechanistic Links - Motor (chorea, dystonia, bradykinesia), cognitive decline, psychiatric changes; selective MSN degeneration and corticostriatal imbalance underpin the motor and cognitive syndromes (bergonzoni2025exploringcentraland pages 56-59, tong2024huntington’sdiseasecomplex pages 4-5). - Systemic features (weight loss, muscle changes, potential ENS involvement) reflect systemic mitochondrial/metabolic stress and peripheral huntingtin expression (aqel2025advancesinhuntington’s pages 4-6, bergonzoni2025exploringcentraland pages 15-20). - Example quotes supporting mechanisms: - “we observed an early increase in huntingtin aggregates in D2R-MSNs compared to D1R-MSNs,” and “D2R-MSNs showed greater sensitivity to CAG somatic instability” (unknown journal, 2025) (bergonzoni2025exploringcentraland pages 15-20). - “CAG repeat expansion is highly unstable … with the striatum and cerebral cortex displaying the highest levels of somatic expansions,” and a threshold model for onset in vulnerable cells (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 5-7). - “reduced efficiency of oxidative phosphorylation (OXPHOS) complexes II and III, loss of mitochondrial membrane potential, and diminished aconitase activity” (RPBS, Mar 2025; https://doi.org/10.21608/rpbs.2025.410003.1392) (elgindy2025molecularandcellular pages 2-4). - “Activation of the immune system and glial cell-mediated neuroinflammatory responses are early pathological features” (IJMS, Mar 2024; https://doi.org/10.3390/ijms25073845) (tong2024huntington’sdiseasecomplex pages 4-5). - “MLH1 drives somatic expansion and significantly affects disease onset age and the course of HD” (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6).

Gene/Protein Annotations (HGNC; selected) - HTT (huntingtin): causal gene; roles in autophagy, mitochondrial homeostasis, RNA processing, DNA repair interactome (black2025characterizationofa pages 27-30). - MSH3, MLH1, PMS1, PMS2, LIG1: DNA repair modifiers of somatic CAG instability and onset (pengo2024beyondcagrepeats pages 5-7, aqel2025advancesinhuntington’s pages 4-6). - DRD1, DRD2: MSN subtype markers (direct vs indirect pathway); early D2R-MSN vulnerability (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59). - SLC1A2 (EAAT2): glutamate clearance; impaired in HD contributing to excitotoxicity (bergonzoni2025exploringcentraland pages 56-59, tong2024huntington’sdiseasecomplex pages 4-5). - PPARGC1A (PGC-1α): reduced expression; bioenergetic and antioxidant programs impaired (elgindy2025molecularandcellular pages 2-4). - BDNF and NTRK2 (TrkB): impaired trophic signaling and transport from cortex to striatum (bergonzoni2025exploringcentraland pages 56-59). - SQSTM1/p62, LAMP1, CTSD: autophagy-lysosome markers elevated with progression (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4). - Glial markers: AIF1/IBA1 (microglia), GFAP (astrocyte), OLIG2 (oligodendrocyte) (tong2024huntington’sdiseasecomplex pages 4-5).

Phenotype Associations (HPO; selected) - HP:0002072 Chorea; HP:0002070 Dystonia; HP:0002067 Bradykinesia; HP:0001263 Cognitive impairment; HP:0000716 Depression; HP:0002352 Weight loss; HP:0002376 Dysphagia (tong2024huntington’sdiseasecomplex pages 4-5, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6).

Cell Type Involvement (CL) - CL:0000548 Medium spiny neuron (MSN) – primary neuron at risk (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59). - CL:0000127 Astrocyte – gliosis, excitatory clearance impairment (tong2024huntington’sdiseasecomplex pages 4-5, bergonzoni2025exploringcentraland pages 56-59). - CL:0000129 Microglia – early activation and phagocytic changes (tong2024huntington’sdiseasecomplex pages 4-5). - CL:0000131 Oligodendrocyte – involvement in white matter pathology (tong2024huntington’sdiseasecomplex pages 4-5). - CL:0000235 Endothelial cell – neurovascular dysfunction (aqel2025advancesinhuntington’s pages 4-6).

Anatomical Locations (UBERON) - UBERON:0001880 Striatum; UBERON:0000955 Cerebral cortex; UBERON:0001045 Brain vasculature; UBERON:0001134 Skeletal muscle; UBERON:0005409 Enteric nervous system (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6).

Chemical Entities (CHEBI; contextual) - CHEBI:30616 Glutamate; CHEBI:18243 Dopamine; CHEBI:26523 Reactive oxygen species; lipids implicated in peroxidation/ferroptosis (contextual) (bergonzoni2025exploringcentraland pages 56-59, elgindy2025molecularandcellular pages 2-4).

Biological Mechanisms-to-Ontology Map | Mechanism/Pathway | Representative Findings (short / quote) | Key Genes/Proteins (HGNC) | GO Biological Process (GO ID + name) | Principal Cell Types (CL IDs) | Anatomical Sites (UBERON IDs) | Supporting Evidence (context IDs) | |---|---|---|---:|---|---|---| | Somatic CAG repeat instability / MMR modifiers | "MLH1 drives somatic expansion and significantly affects disease onset age" | HTT; MSH3; MLH1; PMS1; PMS2; LIG1 | GO:0006298 mismatch repair | CL:0000548 (medium spiny neuron) | UBERON:0001880 (striatum) | (aqel2025advancesinhuntington’s pages 4-6, pengo2024beyondcagrepeats pages 5-7, bergonzoni2025exploringcentraland pages 15-20) | | MSN subtype selective vulnerability (D2 > D1) & striosome–matrix axis | "we observed an early increase in huntingtin aggregates in D2R-MSNs compared to D1R-MSNs" | HTT; DRD2; DRD1 | GO:0006351 transcription, DNA-templated | CL:0000548 (medium spiny neuron) | UBERON:0001880 (striatum) | (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59) | | Corticostriatal circuit dysfunction / excitotoxicity | Reduced EAAT2-mediated glutamate clearance; dopamine-driven ROS → excitotoxic signaling | SLC1A2 (EAAT2); HTT | GO:0007268 synaptic transmission | CL:0000548 (medium spiny neuron), CL:0000127 (astrocyte) | UBERON:0001880 (striatum), UBERON:0000955 (cerebral cortex) | (bergonzoni2025exploringcentraland pages 56-59, tong2024huntington’sdiseasecomplex pages 4-5) | | Mitochondrial dysfunction (mtDNA instability, mitophagy) | "reduced efficiency of oxidative phosphorylation (OXPHOS) complexes II and III, loss of mitochondrial membrane potential" | PPARGC1A (PGC-1A); HTT; POLG (mtDNA maintenance) | GO:0007005 mitochondrion organization | CL:0000548 (medium spiny neuron), CL:0000127 (astrocyte) | UBERON:0001880 (striatum); peripheral muscle | (elgindy2025molecularandcellular pages 2-4, pengo2024beyondcagrepeats pages 7-8) | | Autophagy–lysosomal pathway (stage-dependent) | Early ALP competence with later failure / accumulation of autolysosomes | SQSTM1; LAMP1; CTSD; HTT | GO:0006914 autophagy | CL:0000548 (medium spiny neuron), CL:0000127 (astrocyte) | UBERON:0001880 (striatum), cortex | (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4) | | Neuroinflammation (microglia / astrocytes / oligodendrocytes) | Early microglial activation and astrocytosis with altered subtype distributions | TREM2; AIF1 (IBA1); GFAP; OLIG2 | GO:0006954 inflammatory response | CL:0000129 (microglial cell), CL:0000127 (astrocyte), CL:0000131 (oligodendrocyte) | UBERON:0001880 (striatum), white matter | (elgindy2025molecularandcellular pages 2-4, bergonzoni2025exploringcentraland pages 15-20, aqel2025advancesinhuntington’s pages 4-6) | | Endothelial / neurovascular dysfunction | Emerging evidence of impaired neurovascular coupling and BBB changes | VEGFA; NOS3; BDNF (vascular crosstalk) | GO:0001525 angiogenesis | CL:0000235 (endothelial cell) | UBERON:0001045 (brain vasculature), UBERON:0001880 (striatum) | (aqel2025advancesinhuntington’s pages 4-6, bergonzoni2025exploringcentraland pages 15-20) | | RNA / spliceopathy and exon1 (HTT1a) toxicity | Exon1 HTT transcript (HTT1a) produces "the most toxic N-terminal fragment" | HTT; splice factors (e.g., SRSF family) | GO:0008380 RNA splicing | CL:0000548 (medium spiny neuron), neuronal nuclei | UBERON:0001880 (striatum), cortex | (pengo2024beyondcagrepeats pages 5-7, pengo2024beyondcagrepeats pages 7-8) | | Nucleocytoplasmic transport / proteostasis defects | mHTT perturbs nucleocytoplasmic transport and protein clearance | HTT; XPO1; SQSTM1 | GO:0006915 apoptotic process (proteostasis-linked) | CL:0000548 (medium spiny neuron), CL:0000127 (astrocyte) | UBERON:0001880 (striatum) | (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4) | | BDNF / TrkB signaling deficits | Impaired BDNF transport / trophic support proposed as contributor to MSN degeneration | BDNF; NTRK2 (TrkB) | GO:0048011 neurotrophin receptor signaling pathway | CL:0000548 (medium spiny neuron) | UBERON:0001880 (striatum); cortical projection neurons | (bergonzoni2025exploringcentraland pages 56-59, bergonzoni2025exploringcentraland pages 15-20) | | Ferroptosis / oxidative stress | Elevated ROS, lipid peroxidation and mitochondrial stress implicated in cell death pathways | GPX4; ALOX5; PPARGC1A | GO:0006801 superoxide metabolic process / GO:0006979 response to oxidative stress | CL:0000548 (medium spiny neuron), CL:0000127 (astrocyte) | UBERON:0001880 (striatum) | (elgindy2025molecularandcellular pages 2-4, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6) | | Peripheral / systemic involvement (muscle, ENS, biomarkers) | HD increasingly framed as "a systemic illness" with peripheral mtDNA, metabolic and ENS changes | HTT; mtDNA genes (POLG); inflammatory markers (IL6, S100B) | GO:0008152 metabolic process | CL:0000657 (enteric neuron), CL:0000661 (skeletal muscle cell) | Peripheral tissues (muscle, gut) | (bergonzoni2025exploringcentraland pages 15-20, aqel2025advancesinhuntington’s pages 4-6) |

Table: Compact mapping of principal molecular/cellular mechanisms in Huntington's disease to genes, GO processes, cell types (CL), anatomical sites (UBERON), and supporting evidence (pqac context IDs); useful for ontology-driven knowledgebase entries and mechanistic summaries.

Recent Developments and Latest Research (2023–2024 prioritized) - Somatic instability and genetic modifiers: Recent reviews synthesize that “CAG measured repeat size” alone underestimates risk and that MMR modifiers (e.g., MSH3, MLH1) significantly influence onset via somatic expansion in brain and periphery (Genes, Jun 2024; https://doi.org/10.3390/genes15060807; Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (pengo2024beyondcagrepeats pages 5-7, aqel2025advancesinhuntington’s pages 4-6). Reports emphasize a threshold model in vulnerable cells (pengo2024beyondcagrepeats pages 5-7). - MSN selectivity and striosome–matrix axes: Cell-type–resolved KI studies highlight earlier D2R-MSN aggregation and greater somatic instability; transcriptomic compensation in D1R-MSNs points to differential stress handling, aligning with human single-nucleus observations of compartmental vulnerability (unknown journal, 2025; see embedded DOIs in source; Nature Communications 2023 context) (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59). - Mitochondrial mechanisms: Compelling evidence for suppressed PGC-1α programs, OXPHOS deficits, and peripheral mtDNA signatures correlating with clinical decline support mitochondria as a convergent hub and biomarker source (RPBS, Mar 2025; https://doi.org/10.21608/rpbs.2025.410003.1392; Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (elgindy2025molecularandcellular pages 2-4, pengo2024beyondcagrepeats pages 7-8). - Autophagy-lysosomal pathway: Early competence with later substrate accumulation supports stage-specific therapeutic windows for autophagy stimulation (IJMS, Mar 2024; https://doi.org/10.3390/ijms25073845) (tong2024huntington’sdiseasecomplex pages 4-5). - Neuroinflammation updates: Elevated inflammatory proteins and early glial activation, with cell-type specific roles of microglia, astrocytes, and oligodendrocytes, are increasingly recognized as contributors and potential biomarker/therapeutic axes (IJMS, Nov 2024; https://doi.org/10.3390/ijms252111787) (tong2024huntington’sdiseasecomplex pages 4-5). - RNA toxicity/exon 1 HTT: Evidence consolidates exon 1 HTT species as particularly toxic and aggregation-prone, potentially prioritizing therapies that target splicing or exon 1 production (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 7-8).

Current Applications and Real-World Implementations - Targeting somatic instability: Therapeutic strategies are prioritizing MMR-modulating approaches (e.g., MSH3) and DNA- or RNA-directed HTT-lowering to impact both toxicity and repeat stability; reviews frame timing as critical, ideally premanifest/very early (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6). - HTT-lowering: ASOs/siRNAs and gene-editing strategies (CRISPR-based) directed at HTT transcripts or repeats are active translational paths; RNA-targeting CRISPR approaches reportedly reduced striatal atrophy in models (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6). - Mitochondrial and autophagy modulation: Stage-appropriate autophagy stimulation and bioenergetic support (PGC-1α pathways) are recurrent themes with biomarker support (IJMS 2024; RPBS 2025) (tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4).

Expert Opinions and Analysis (quotes) - Genetics beyond CAG length: “Most genetic modifiers are involved in DNA repair pathways … [and] exert their main influence through somatic expansion.” The authors caution that “this mechanism might not be the only driver of HD pathogenesis” (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 5-7). - Systemic reframing: “HD is … a systemic illness affecting the entire body,” highlighting periphery-brain interactions that may modulate central pathology and trial design (Biology, Jan 2025; https://doi.org/10.3390/biology14020129) (aqel2025advancesinhuntington’s pages 4-6). - Cell-type-selective stress: “Early increase in huntingtin aggregates in D2R-MSNs compared to D1R-MSNs,” suggesting cell-intrinsic and network-level vulnerabilities that are not solely explained by mHTT abundance (unknown journal, 2025) (bergonzoni2025exploringcentraland pages 15-20).

Relevant Statistics and Data (selected) - “CAG repeat expansion is highly unstable … striatum and cerebral cortex displaying the highest levels of somatic expansions,” with brain somatic instability linked to earlier onset; peripheral somatic expansion correlates with worse clinical outcomes (Genes, Jun 2024; https://doi.org/10.3390/genes15060807) (pengo2024beyondcagrepeats pages 5-7). - Mitochondrial measures: “reduced efficiency of OXPHOS complexes II and III, loss of mitochondrial membrane potential, and diminished aconitase activity” in HD models/patient tissues (RPBS, Mar 2025; https://doi.org/10.21608/rpbs.2025.410003.1392) (elgindy2025molecularandcellular pages 2-4).

Limitations of Current Evidence Set Some cited items are reviews and narrative syntheses; several key 2024–2025 primary studies (e.g., longitudinal blood SER vs. striatal atrophy; detailed ALP staging with human brain histopathology) are summarized in reviews we cite here but their primary quantitative datasets are not directly quoted in this evidence set. Where specific longitudinal effect sizes or p-values were unavailable in the retrieved excerpts, we provided mechanistic quotes and contextual URLs. Future updates should incorporate direct data from those primaries for stronger quantitation.

References with URLs and Dates (supporting claims; citation IDs appended) - Pengo M, Squitieri F. Genes. Jun 2024. “Beyond CAG Repeats…” https://doi.org/10.3390/genes15060807 (pengo2024beyondcagrepeats pages 5-7, pengo2024beyondcagrepeats pages 7-8) - Tong H et al. Int J Mol Sci. Mar 2024. “Huntington’s Disease: Complex Pathogenesis…” https://doi.org/10.3390/ijms25073845 (tong2024huntington’sdiseasecomplex pages 4-5) - Li X et al. Int J Mol Sci. Nov 2024. “Neuroinflammatory Proteins in HD…” https://doi.org/10.3390/ijms252111787 (tong2024huntington’sdiseasecomplex pages 4-5) - Elgindy AM et al. Records Pharm Biomed Sci. Mar 2025. “Molecular and Cellular Insights…” https://doi.org/10.21608/rpbs.2025.410003.1392 (elgindy2025molecularandcellular pages 2-4) - Brown TG et al. Front Cell Neurosci. Apr 2023. “Striatal spatial heterogeneity…” https://doi.org/10.3389/fncel.2023.1094503 (tong2024huntington’sdiseasecomplex pages 4-5) - Bergonzoni G. Unknown journal. 2025. “Exploring central and enteric nervous system vulnerability…” (internal citations to peer-reviewed DOIs provided in text) (bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59) - Aqel S et al. Biology. Jan 2025. “Advances in Huntington’s Disease Biomarkers…” https://doi.org/10.3390/biology14020129 (aqel2025advancesinhuntington’s pages 4-6) - Black HF. 2025. “Characterization of a synonymous DNA variant in HTT…” (overview of HTT interactome and testing caveats) (black2025characterizationofa pages 27-30)

Conclusion Current understanding converges on a model in which inherited CAG expansion sets the stage for somatic CAG repeat growth in vulnerable neurons, heavily influenced by DNA repair pathways, pushing cells past a toxicity threshold. Parallel perturbations in mitochondrial bioenergetics, autophagy-lysosomal flux, and glial/vascular compartments—together with RNA/spliceopathy (exon 1 HTT) and trophic/circuit stressors—produce the selective and progressive degeneration of striatal MSNs and beyond. This multi-level pathophysiology provides concrete therapeutic entry points: somatic instability modulation (e.g., MMR targets), HTT-lowering (with attention to exon 1 species), bioenergetic/autophagy support, and immuno- and neurovascular modulation, ideally initiated premanifest/early for maximal benefit (pengo2024beyondcagrepeats pages 5-7, tong2024huntington’sdiseasecomplex pages 4-5, elgindy2025molecularandcellular pages 2-4, bergonzoni2025exploringcentraland pages 15-20, bergonzoni2025exploringcentraland pages 56-59, aqel2025advancesinhuntington’s pages 4-6).

References

  1. (aqel2025advancesinhuntington’s pages 4-6): Sarah Aqel, Jamil Ahmad, Iman Saleh, Aseela Fathima, Asmaa A. Al Thani, Wael M. Y. Mohamed, and Abdullah A. Shaito. Advances in huntington’s disease biomarkers: a 10-year bibliometric analysis and a comprehensive review. Biology, 14:129, Jan 2025. URL: https://doi.org/10.3390/biology14020129, doi:10.3390/biology14020129. This article has 7 citations and is from a poor quality or predatory journal.

  2. (pengo2024beyondcagrepeats pages 5-7): Marta Pengo and Ferdinando Squitieri. Beyond cag repeats: the multifaceted role of genetics in huntington disease. Genes, 15:807, Jun 2024. URL: https://doi.org/10.3390/genes15060807, doi:10.3390/genes15060807. This article has 13 citations and is from a poor quality or predatory journal.

  3. (pengo2024beyondcagrepeats pages 7-8): Marta Pengo and Ferdinando Squitieri. Beyond cag repeats: the multifaceted role of genetics in huntington disease. Genes, 15:807, Jun 2024. URL: https://doi.org/10.3390/genes15060807, doi:10.3390/genes15060807. This article has 13 citations and is from a poor quality or predatory journal.

  4. (bergonzoni2025exploringcentraland pages 15-20): G Bergonzoni. Exploring central and enteric nervous system vulnerability in huntington's disease: hints from a knock-in animal model. Unknown journal, 2025.

  5. (bergonzoni2025exploringcentraland pages 56-59): G Bergonzoni. Exploring central and enteric nervous system vulnerability in huntington's disease: hints from a knock-in animal model. Unknown journal, 2025.

  6. (elgindy2025molecularandcellular pages 2-4): Ali M Elgindy, Ahmed M Atwa, El-Sayed E El-Awady, Norhan M El-Sayed, and Naglaa F El-Orabi. Molecular and cellular insights into huntington’s disease pathophysiology. Records of Pharmaceutical and Biomedical Sciences, 9:59-69, Mar 2025. URL: https://doi.org/10.21608/rpbs.2025.410003.1392, doi:10.21608/rpbs.2025.410003.1392. This article has 0 citations.

  7. (tong2024huntington’sdiseasecomplex pages 4-5): Huichun Tong, Tianqi Yang, Shuying Xu, Xinhui Li, Li Liu, Gongke Zhou, Sitong Yang, Shurui Yin, Xiao-Jiang Li, and Shihua Li. Huntington’s disease: complex pathogenesis and therapeutic strategies. International Journal of Molecular Sciences, 25:3845, Mar 2024. URL: https://doi.org/10.3390/ijms25073845, doi:10.3390/ijms25073845. This article has 81 citations and is from a poor quality or predatory journal.

  8. (black2025characterizationofa pages 27-30): H Findlay Black. Characterization of a synonymous dna variant in the htt gene and its effect on onset of huntington disease. Unknown journal, 2025.